Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Tosoh Bioscience Inc.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from OncoLens and Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Pillar Biosciences.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Illumina.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
March 2024—Randox has released its female bladder cancer array, designed to help clinicians stratify patients presenting with hematuria. The array detects interleukin-12p70, interleukin-13, midkine, and clusterin from a single urine sample to determine an individual’s biomarker risk score. A person’s risk for developing bladder cancer is determined by combining the biomarker risk score with clinical risk scores generated using the company’s algorithms.
March 2024—Bruker Corp. has entered into a definitive share purchase agreement to acquire EliTechGroup for €870 million (about $940 million) in cash, excluding EliTech’s clinical chemistry business. Bruker expects to close the transaction in the second quarter of this year.
March 2024—Roche has entered into a definitive agreement to acquire select parts of the LumiraDx group related to LumiraDx’s point-of-care technology. The transaction is expected to close by the middle of this year, after which the acquired entities will be fully integrated into Roche Diagnostics.
March 2024—Immunexpress announced FDA clearance of EDTA blood compatible cartridges for use with the SeptiCyte Rapid test. SeptiCyte Rapid is a sample-to-answer, cartridge-based, host response molecular test for sepsis using reverse transcription polymerase chain reaction to quantify the relative expression levels of host response genes isolated from whole blood. It is intended for in vitro diagnostic use and runs on the Biocartis Idylla platform.
March 2024—Binx Health announced it has entered into a national distribution agreement with Cardinal Health to expand access to care with its CLIA-waived, FDA-cleared Binx IO. The molecular point-of-care platform is used to detect chlamydia and gonorrhea in male and female patient samples and provides results in about 30 minutes.
March 2024—Cepheid announced it has received FDA clearance with a CLIA waiver for the Xpert Xpress MVP, a multiplex vaginal panel that can now be performed in near-patient settings. The test is intended to aid in the diagnosis of bacterial vaginosis, vulvovaginal candidiasis, and trichomoniasis from a single specimen. It runs on Cepheid’s GeneXpert Xpress instruments and provides results within an hour.
March 2024—OGT announced the opening of state-of-the-art facilities in Oxford Technology Park in the U.K. The facilities will drive development of OGT’s SureSeq next-generation sequencing product portfolio, as well as deliver expert-led training and opportunities for collaboration. Customers can receive face-to-face support with OGT’s field application specialists at the new facility and in-depth demonstrations of the company’s NGS and FISH products.
March 2024—Copan Diagnostics announced the third FDA 510(k) clearance for its Colibrí automated ID/AST preparation instrument. The in vitro diagnostic specimen preparation system has been cleared to prepare MALDI-TOF targets for qualitative identification and microbial suspension for the Beckman Coulter MicroScan WalkAway antimicrobial susceptibility testing system for qualitative testing of isolated colonies of Gram-negative and Gram-positive bacterial species grown on solid culture media.
March 2024—Qiagen Digital Insights announced its enhanced CLC Genomics Workbench Premium with LightSpeed technology now supports next-generation sequencing for somatic cancer secondary analysis. The software accelerator converts raw sequencing data in FASTQ files to interpretable lists of genetic variants in variant call format files. Qiagen says LightSpeed can analyze a 275-gene comprehensive cancer panel at 3377× coverage in six minutes for less than $0.72 per test within standard cloud environments, or laboratories can run the Qiagen CLC LightSpeed technology on existing local hardware with similar performance.
March 2024—BD Biosciences has released its BD Horizon RealBlue 744 and 705 laser-specific reagents, designed to reduce spillover and well suited for low- to medium-expression surface and intracellular markers. RB 744 can be used on five-laser BD FacSymphony analyzers and spectral flow cytometers. RealBlue 705 is an alternative to BD PerCP-Cy5.5 and BD Brilliant Blue 700 reagents and is compatible with conventional and spectral flow cytometry.
